<DOC>
	<DOCNO>NCT00744367</DOCNO>
	<brief_summary>This 3 arm study ass efficacy taspoglutide glycemic control ( assessed HbA1c ) patient type 2 diabetes mellitus inadequately control metformin plus pioglitazone , compare placebo 24 week treatment . Patients randomize one 3 treatment arm : taspoglutide 10mg weekly , taspoglutide 20 mg weekly ( 4 week taspoglutide 10 mg weekly ) placebo , addition continue stable metformin plus pioglitazone treatment . After first 24 week patient placebo switch taspoglutide 10mg weekly taspoglutide 20mg weekly ( 4 week taspoglutide 10mg weekly . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Taspoglutide Versus Placebo Treatment Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes receive pioglitazone ( &gt; = 30 mg/day ) metformin ( &gt; = 1500 mg/day ) least 12 week prior screen ; HbA1c &gt; =7.0 % &lt; =10.0 % screening ; BMI &gt; = 25 ( &gt; 23 Asians ) &lt; =45 kg/m2 screening ; stable weight +/5 % least 12 week prior screen . history type 1 diabetes mellitus acute metabolic diabetic complication ketoacidosis hyperosmolar coma previous 6 month ; evidence clinically significant diabetic complication ; clinically symptomatic gastrointestinal disease ; myocardial infarction , coronary artery bypass surgery , posttransplantation cardiomyopathy stroke within previous 6 month ; know hemoglobinopathy chronic anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>